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Abstract
Introduction: The single nucleotide polymorphism (SNP) rs6822844 within the KIAA1109-TENR-IL2-IL21 gene cluster has 
been associated with rheumatoid arthritis (RA). Other variants within this cluster, including rs17388568 that is not in 
linkage disequilibrium (LD) with rs6822844, and rs907715 that is in moderate LD with rs6822844 and rs17388568, have 
been associated with a number of autoimmune phenotypes, including type 1 diabetes (T1D). Here we aimed to: one, 
confirm at a genome-wide level of significance association of rs6822844 with RA and, two, evaluate whether or not 
there were effects independent of rs6822844 on RA at the KIAA1109-TENR-IL2-IL21 locus.
Methods: A total of 842 Australasian RA patients and 1,115 controls of European Caucasian ancestry were genotyped 
for rs6822844, rs17388568 and rs907715. Meta-analysis of these data with published and publicly-available data was 
conducted using STATA.
Results: No statistically significant evidence for association was observed in the Australasian sample set for rs6822844 
(odds ratio (OR) = 0.95 (0.80 to 1.12), P = 0.54), or rs17388568 (OR = 1.03 (0.90 to 1.19), P = 0.65) or rs907715 (OR = 0.98 
(0.86 to 1.12), P = 0.69). When combined in a meta-analysis using data from a total of 9,772 cases and 10,909 controls 
there was a genome-wide level of significance supporting association of rs6822844 with RA (OR = 0.86 (0.82 to 0.91), P = 
8.8 × 10-8, P = 2.1 × 10-8 including North American Rheumatoid Arthritis Consortium data). Meta-analysis of rs17388568, 
using a total of 6,585 cases and 7,528 controls, revealed no significant association with RA (OR = 1.03, (0.98 to 1.09); P = 
0.22) and meta-analysis of rs907715 using a total of 2,689 cases and 4,045 controls revealed a trend towards association 
(OR = 0.93 (0.87 to 1.00), P = 0.07). However, this trend was not independent of the association at rs6822844.
Conclusions: The KIAA1109-TENR-IL2-IL21 gene cluster, that encodes an interleukin (IL-21) that plays an important role 
in Th17 cell biology, is the 20th locus for which there is a genome-wide (P ≤ 5 ×10-8) level of support for association with 
RA. As for most other autoimmune diseases, with the notable exception of T1D, rs6822844 is the dominant association 
in the locus. The KIAA1109-TENR-IL2-IL21 locus also confers susceptibility to other autoimmune phenotypes with a 
heterogeneous pattern of association.
Introduction
Genetic associations implicate aberrant activation and
regulation of autoreactive T-cells as central to RA. In
addition to the established human leukocyte antigen
locus DRB1, other genes more recently confirmed (either
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through wide replication or combined analysis at a
genome-wide level of significance, P ≤ 10-8) as playing a
role in the development of RA are the protein tyrosine
phosphatase non-receptor 22 gene (PTPN22) [1], cyto-
toxic T-lymphocyte associated 4 (CTLA4) [2], an inter-
genic region on human chromosome 6 [3,4], signal
transducer and activator of transcription 4 (STAT4) [5,6],
the TNF receptor-associated factor 1 region (TRAF/C5)
[3,7,8], CD40 [9,10], B-lymphocyte kinase (BLK) and the
NF-kB family member c-Rel [11]. Aside from HLA-DRB1
and PTPN22, the effects are weak (odds ratio (OR) < 1.3).
Most of these loci are also implicated as risk factors in
other autoimmune phenotypes [12].
The KIAA1109-TENR-IL2-IL21 region has been associ-
ated with a number of autoimmune phenotypes including
type 1 diabetes (T1D) [13], ulcerative colitis [14], Crohn's
disease [15], celiac disease [16], Graves' disease (GD) [13],
systemic lupus erythematosus (SLE) [17], psoriatic arthri-
tis [18], and juvenile idiopathic arthritis [19] (Table 1).
There have been several studies testing this region for
association with RA in European Caucasian sample sets,
with varying levels of supporting evidence (0.24 >P > 2.8
× 10-4) [6,12,20,21]. There is extensive linkage disequilib-
rium across the region, hampering fine-mapping efforts
[13], however it is clear that there are two independent
autoimmune associated regions within the KIAA1109-
TENR-IL2-IL21 gene cluster. Here, we aimed to consoli-
date all available data on two SNPs independently associ-
ated with autoimmunity within the KIAA1109-TENR-
IL2-IL21 gene cluster: rs6822844 (minor allele protective)
and  rs17388568  (minor allele susceptible), each into a
single meta-analysis of association with RA that included
previously published data, new genotype data from Aus-
tralasia, and publicly-available data from the Wellcome
Trust Case Control Consortium (WTCCC) [22].
Materials and methods
Study participants
The Australasian European Caucasian RA samples con-
sist of 842 patients of whom 31% were male. For the RA
patients for whom data were available, 81% (601/739)
were rheumatoid factor (RF) positive, 68% (333/491) were
anti-cyclic citrullinated peptide (CCP) antibody positive
and 80% (657/820) carried the HLA-DRB1 shared epitope
(SE). RA diagnosis was confirmed in all patients by a
rheumatologist using the ACR criteria [23]. Patients were
recruited from hospital outpatient clinics in the Auck-
land, Bay of Plenty, Wellington, Christchurch and Otago
regions of New Zealand, and from Adelaide in South
Australia. European Caucasian control subjects (n = 505)
without RA were recruited from the Otago and Auckland
regions of New Zealand and were all > 17 years of age. A
further 610 controls recruited from the Otago region had
been genome-wide scanned using the Affymetrix
Genome-Wide Human SNP Array 6.0 [24]. These elderly
controls were > 60 years of age and in good general
health. All subjects provided informed written consent
and ethical approval for this study was given by the New
Zealand Multi-region Ethics Committee and the Lower
South Ethics Committee, and the Research and Ethics
Committee of the Repatriation General Hospital, Ade-
laide. Genomic DNA was extracted from peripheral
blood samples using a guanidine isothiocyanate-chloro-
form based (RA patients and controls) or modified salting
out (elderly controls) extraction method.
Genotype generation
Study participants were genotyped for rs6822844,
rs17388568  and  rs907715  using TaqMan®, assays ID
C_28983601_10, ID C_33129431_10 and ID
C_8949748_10 (Applied Biosystems, Foster City, CA,
USA) respectively. Imputed RA and control genotypes
were obtained for rs6822844, rs17388568 and rs907715
from 100% of the WTCCC dataset (1,856 cases, 2,933
controls) using the publicly available WTCCC data [22]
using the program IMPUTE [25] and HapMap (NCBI
Build 36 (db126b)) CEU data as reference haplotype set.
Of the Australasian case sample set, 99.1% of subjects for
rs6822844, 99.1% of subjects for rs17388568 and 98.9% of
subjects for rs9077015 were successfully genotyped and,
for the 505 member control sample set, 97.4% of subjects
for  rs6822844, 99.4% of subjects for rs17388568  and
99.4% of subjects for rs9077015 were successfully geno-
typed. The remaining New Zealand control genotypes (n
= 610) were obtained from the genome-wide data, with
100% successfully genotyped for rs17388568 and 99.6%
imputed for rs6822844 and rs907715.
Statistical analysis
Genotype data were managed using the BC|SNPmax sys-
tem (Biocomputing Platforms Ltd, Espoo, Finland). Test-
ing for departures from Hardy-Weinberg equilibrium, for
the significance of any difference in minor allele frequen-
cies between patients and controls, calculating odds
ratios and conditional association testing was done using
the PLINK software package [26]. Logistic regression
analysis was applied to the Australasian case-control
sample set to stratify data according to gender, RF, CCP
and SE status using the STATA 8.0 data analysis and sta-
tistics software package (StataCorp, College Station,
Texas, USA). Meta-analysis was done using the STATA
8.0 metan software package and cumulative P-  values
reported. The Mantel-Haenszel test was used to estimate
the average conditional common odds ratio between
these two independent cohorts and to test for heteroge-
neity between the groups. P-  values from the North
American Rheumatoid Arthritis Consortium (NARAC)
study [3], which could not be combined using meta-anal-H
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Table 1: Summary table of SNPs described in the literature and linkage disequilibrium relationship with rs6822844 and rs17388568
Location 
(dbSNP130)
r2 in relation to SNP Gene Disease
SNP rs6822844 rs17388568 T1D CeD GD UC CD JIA PSA PS RA SLE
rs6822844 123728871 1 0.07 - [13,21]
- -
[16,40,41]
- -
[14,15,38]
- -
[14,15]
- -
[19]
- -
[18]
- -
[18]
=
[6,12,21]
-
rs13151961 123334952 0.89 0.10 KIAA1109 (intron) [16,20,40,41]
- -
[14]
- -
[14]
-
[18]
- -
[18]
=
rs6840978 123774157 0.73 0.13 - [16,40,42]
- -
[14,38]
- -
[14]
-
rs13119723 123437763 0.65 0.07 KIAA1109 (intron) [16,40,42]
- -
[14,38]
- -
[14]
-
rs11938795 123292459 0.53 0.16 - [16,42]
- -
[15]
-
[15]
- -
rs11734090 123447563 0.53 0.16 KIAA1109 (intron) [16,42]
-
rs12642902 123727951 0.45 0.22 - [16,42]
-
rs7684187 123560609 0.44 0.19 TENR (intron) [16,42]
-
[18]
- -
[18]
-
rs907715 123754503 0.41 0.22 IL21 (intron) [17]
- -
rs17388568 123548812 0.07 1 TENR (intron) [13]
+
[13]
+
[12]
=
rs2221903 123758362 0.08 0.88 IL21 (intron) [17]
+
rs3136534 123589223 0.10 0.82 - [13]
+
rs4505848 123351942 0.10 0.82 KIAA1109 (intron) [43]
+
[20]
=
rs6836189 123760791 - - IL21 (intron) [13]
+
CD: Crohn's disease; CeD: Celiac's disease; GD: Grave's disease; JIA: juvenile idiopathic arthritis; RA: rheumatoid arthritis; T1D: type 1 diabetes; PS: psoriasis; PSA: psoriatic arthritis; SLE: systemic lupus 
erythematosus; UC: ulcerative colitis. The SNPs are arranged into separate LD blocks in relation to rs6822844 and rs17388568. Key to symbols: OR < 0.8, - -; OR 0.8 to < 1.0, -; no effect, =; OR > 1.0 to 
1.2, +; OR > 1.2, +Hollis-Moffatt et al. Arthritis Research & Therapy 2010, 12:R116
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ysis owing to unavailability of allele counts, were com-
bined using Fisher's method [27].
Results
We examined rs6822844, rs17388568 and rs907715. The
latter SNP was chosen because it had been associated with
risk of the systemic autoimmunity SLE in a single study
[17] (OR = 0.78, P = 0.002), was in weak LD with both
rs6822844 and rs17388568 and we hypothesized that it
could represent a possible third effect within the
KIAA1109-TENR-IL2-IL21  cluster, perhaps specific to
systemic autoimmunity. The imputed genotype data from
the WTCCC RA case-control sample revealed no signifi-
cant association between rs6822844 and RA (Table 2; OR
= 0.91 (0.82 to 1.02); P = 0.10) (the WTCCC samples did
not overlap with those analysed in Barton et al. [12]). SNP
rs6822844 had been genotyped in the NARAC sample set
[3], revealing nominal evidence for a protective effect of
the minor allele (Table 2; OR = 0.84 (0.74 to 0.96), P =
0.011). We then genotyped rs6822844 across the Austral-
asian case-control sample set, finding no evidence for
association between rs6822844 and RA (T a ble 2; OR =
0.95 (0.80 to 1.12), P = 0.54) although, consistent with the
other association studies, the OR was less than one. Meta-
analysis of all available data was undertaken (Figure 1).
Zhernakova  et al. [21] and Coenen et al. [28] both
reported association of the KIAA1109-TENR-IL2-IL21
region with RA in overlapping Dutch case-control
cohorts. We used data from the former study, as it was the
only one to type rs6822844. The meta-analysis provided
very strong (genome-wide) support for rs6822844 playing
a role in the development of RA (OR = 0.86 (0.82 to 0.91),
P = 8.8 × 10-8). The NARAC GW AS data (OR rs6822844 =
0.84 (0.74-0.96), P = 0.011) [7] were combined with the
meta-analysis result, yielding P = 2.1 × 10-8.
For rs17388568, the genotype data from the WTCCC
case-control sample revealed a weak association between
rs17388568  and RA, with a susceptibility effect of the
minor allele (Table 3; OR = 1.14 (1.04 to 1.25), P = 0.005).
We genotyped rs17388568 across the Australasian case-
control sample set, finding no evidence for association
between rs17388568 and RA (Table 3; OR = 1.03 (0.90 to
1.19), P = 0.66), a result that was consistent with a study
of a UK case-control sample set by Barton et al. [12]
(Table 3; OR = 0.97 (0.91 to 1.05), P = 0.47). Meta-analysis
of all the available data was done (Figure 2), with the
combined analysis showing no significant role for
Figure 1 Meta-analysis of the KIAA1109-TENR-IL2-IL21 SNP, rs6822844. Combined odds ratio values from data presented in Table 2. There was 
no evidence for heterogeneity between sample sets (P = 0.25).
Odds ratio
.607839 1 1.64517
Study  % Weight
 Odds ratio
 (95% CI)
 0.92 (0.82,1.02)  WTCCC  25.8
 0.72 (0.61,0.86)  Zhernakova  10.9
 0.85 (0.65,1.12)  Teixeira   4.1
 0.86 (0.79,0.94)  Barton  39.6
 0.84 (0.71,1.00)  Daha   9.7
 0.95 (0.80,1.12)  Australasian   9.9
 0.86 (0.82,0.91)  Overall (95% CI)Hollis-Moffatt et al. Arthritis Research & Therapy 2010, 12:R116
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rs17388568 in the development of RA (OR = 1.03, (0.98
to 1.09), P = 0.22). At rs907715, the imputed WTCCC
genotype data also revealed a weak association (Table 3;
OR = 0.92 (0.84 to 1.00), P = 0.055). Genotyping of the
Australasian sample set and combined analysis with the
WTCCC data (T able 3; Figure 3) slightly weakened the
evidence for association of rs907715 with RA (OR = 0.93
(0.87 to 1.00), P = 0.07). Neither rs17388568 nor rs907715
nor any surrogate SNP was present in the NARAC data.
Given the moderate LD between rs907715 and rs6822844
(Table 1), rs907715 was tested for association in the com-
bined WTCCC and Australasian samples conditional on
genotype at rs6822844.  This revealed that the trend
towards association seen for rs907715 was not indepen-
dent of the association seen at rs6822844 (P = 0.38).
The Australasian sample set was further examined by
stratifying rs6822844 according to gender, RF, CCP and
SE status (Table 4). This revealed no specific association
to any particular sub-phenotypes analysed (P > 0.05). It
should be noted that the power to detect association with
sub-phenotype within the Australasian sample set was
limited; for example, in the analysis with the largest
amount of data available (RF) there was adequate power
(> 70%) to detect an allele frequency difference between
RF positive and negative cases only when the difference
was equivalent to an OR > 1.5.
Discussion
Here we have combined published studies testing associa-
tion of two SNPs, rs6822844  and  rs17388568, located
within the KIAA1109-TENR-IL2-IL21 region with RA: the
former with two Dutch [6,21], one UK [12], and one West-
ern Europe sample set [20]; and the latter with one UK
sample set [12] - along with new Australasian data, and
data from the WTCCC [22]. Meta-analysis (Figure 1)
showed a consistent protective effect for the minor allele
of rs6822844 with RA (OR = 0.86, P = 8.8 × 10-8). A similar
protective effect was also observed in the NARAC GWAS
Table 2: Association analysis of the KIAA1109-TENR-IL2-IL21 SNP rs6822844 with RA in seven European case control sample 
sets
Genotype, no. (frequency)1,2 Minor allele, 
no. (frequency)
OR [95% CI] P
Sample Set 1/1 1/2 2/2
WTCCC [22]
Case 1,242 (0.669) 553 (0.298) 61 (0.033) 675 (0.181) 0.91 (0.82 to 1.02) 0.10
Control 1,881 (0.642) 958 (0.326) 94 (0.032) 1,146 (0.195)
Zhernakova [21]
Case 748 (0.739) 243 (0.240) 21 (0.021) 285 (0.141) 0.72 (0.61 to 0.86) 2.0 × 10-4
Control 613 (0.663) 280 (0.303) 31 (0.034) 342 (0.185)
NARAC [3]
Case NA NA NA NA 0.84 (0.74 to 0.96) 0.011
C o n t r o lN AN AN A N A
Teixeira [20]
Case 327 (0.753) 99 (0.228) 8 (0.018) 115 (0.132) 0.85 (0.65 to 1.12) 0.24
Control 313 (0.721) 110 (0.253) 11 (0.025) 132 (0.152)
Barton [12]
Case 2,739 (0.705) 1,052 (0.271) 95 (0.024) 1,242 (0.160) 0.86 (0.79 to 0.94) 5.4 × 10-4
Control 2,326 (0.674) 1,003 (0.290) 125 (0.036) 1,253 (0.181)
Daha [6]
Case NA NA NA 285 (0.162) 0.84 (0.70 to 1.00) 0.051
C o n t r o lN AN AN A 3 2 5  ( 0 . 1 8 8 )
Australasian
Case 583 (0.699) 221 (0.265) 30 (0.036) 281 (0.168) 0.95 (0.80 to 1.12) 0.54
Control 743 (0.674) 330 (0.299) 29 (0.026) 388 (0.176)
(1) There were no significant departures from Hardy-Weinberg equilibrium, all P > 0.06
(2) Genotype data were imputed in the WTCCC sample set, and directly genotyped in all othersHollis-Moffatt et al. Arthritis Research & Therapy 2010, 12:R116
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for rs6822844 (OR = 0.84, P = 0.011), with combined evi-
dence for association with RA of P = 2.1 × 10-8 when com-
bined with our meta-analysis P- value. Our analysis used
the same European Caucasian RA sample sets recently
meta-analysed by Maita et al. [29], with the addition of the
WTCCC, Barton et al. [12], Australasian and NARAC [3]
data. Meta-analysis of the T1D-associated SNP
rs17385868 (Figure 2) on the other hand, did not reveal
any significant association between the minor allele of
rs17388568 and RA (OR = 1.03, P = 0.22). Note that SNP
rs4505848, in strong LD with rs17385868, is more strongly
associated with T1D (Table 1). Whilst there was weak evi-
dence for association at rs907715 (Table 3), in a direction
consistent with that previously observed in SLE [17], this
effect appears to be dependent on rs6822844. When this
paper was under review a genome-wide association scan
meta-analysis in RA was published, in 5,539 autoantibody
positive cases and 20,169 controls of European descent
[30], with P = 7 × 10-4 at rs6822844. We meta-analysed
these data with data presented in Table 2 (removing the
overlapping WTCCC samples), yielding OR = 0.86 (0.82
to 0.89), P < 1 × 10-10. The rs6822844 data provide com-
pelling evidence supporting a role for the KIAA1109-
TENR-IL2-IL21 locus in etiology of RA in Caucasian pop-
ulations. Including the HLA region and the 10 loci con-
firmed by Stahl et al. [30] (note that Stahl et al. did not
confirm  KIAA1109-TENR-IL2-IL21  at a genome-wide
level of significance), KIAA1109-TENR-IL2-IL21  is the
20th locus associated with RA at a genome-wide level of
significance (P ≤ 5 × 10-8). The association at rs6822844
dominates at this locus, with no evidence for an indepen-
dent effect at rs17385868, as is seen in T1D (Table 1) [13].
The KIAA1109-TENR-IL2-IL21 region was first impli-
cated in autoimmunity after a GWAS in T1D [13,22] and
has since been associated, also with a genome-wide level
of support, with celiac disease [16] and ulcerative colitis
[14] and, with lower supporting evidence, with SLE, pso-
riatic arthritis, Graves' disease and juvenile idiopathic
arthritis [13,17-19] (Table 1). The region is characterized
by a high degree of linkage disequilibrium [13], meaning
that the underlying disease-causing variant(s) and gene(s)
have not yet been determined. Collectively, these data
point to at least two independent associations within the
KIAA1109-TENR-IL2-IL21  region, with the pattern of
association differing between autoimmune phenotypes
(Table 1); one marked by rs17388568 (in the TENR gene)
Figure 2 Meta-analysis of the KIAA1109-TENR-IL2-IL21 SNP, rs17388568. Combined odds ratio values from the WTCCC [22], Barton et al. [12], and 
the Australasian case-control sample sets. There was evidence for heterogeneity between sample sets (P = 0.03)
Odds ratio
.799909 1 1.25014
Study  % Weight
 Odds ratio
 (95% CI)
 1.14 (1.04,1.25)  WTCCC  31.1
 0.97 (0.91,1.05)  Barton  55.2
 1.03 (0.90,1.19)  Australasian  13.7
 1.03 (0.98,1.09)  Overall (95% CI)Hollis-Moffatt et al. Arthritis Research & Therapy 2010, 12:R116
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and the other by rs6822844 (which maps between IL-2
and IL-21). There is no appreciable linkage disequilib-
rium between rs17388568  and  rs6822844  (r2 = 0.07 in
HapMap CEU samples). Different patterns of association
are evident in the different autoimmune phenotypes. For
example (referring to the risk conferred by the minor
allele), susceptibility at rs17388568  and protection at
rs6822844 is observed in T1D [13,21], some evidence for
protection is seen at rs17388568 in Graves' disease [13],
there is no evidence for association of rs17388568  (or
m a r k e r s  i n  h i g h  L D )  w i t h  R A  ( F i g u r e  2 )  w h e r e a s
rs6822844  confers protection (Table 1). The studies in
Crohn's disease, ulcerative colitis, celiac disease, psoriatic
arthritis, and JIA are consistent in reporting the
rs6822844-mediated minor allele protective effect [14-
16,18,19] (Table 1), with little data available on
rs17388568 in comparison to rs6822844. The single study
in SLE [17] did not include SNPs in LD with rs6822844,
however there was evidence for a susceptibility effect at
rs17388568 (using rs2221903 which is in strong LD with
rs17388568, Table 1). Collectively, these studies point to
heterogeneity at rs17388568 between RA and other auto-
immune phenotypes (T1D, GD, SLE) with which RA
shares other genes and clinical features.
Within the KIAA1109-TENR-IL2-IL21 gene cluster, IL-
21 is of particular interest in the context of RA, and the
Th1/Th17 axis in which IL-23R is involved. IL-21 is
required for differentiation of naïve human CD4+ T cells
into Th17 cells [31], whereas IL-23 is critical in the
expansion and maintenance of Th17 cells [32,33]. It is
important to note that Th17 cells produce a variety of
cytokines including IL-17A, IL-17F, IL-21 and IL-22.
Human studies have demonstrated that IL-21 receptor
(IL-21R)-positive cells are significantly increased in
i n f l a m e d  s y n o v i a l  t i s s u e s  o f  R A  p a t i e n t s  c o m p a r e d  t o
controls and that IL-21 enhances local T-cell activation,
proliferation and proinflammatory cytokine secretion
[34,35]. Alongside these findings, animal studies demon-
strate that IL-21R deficient mice have normal T-cell and
NK cell development but fail to develop spontaneous
autoimmune disease suggesting that IL-21 plays a vital
role in the development of autoimmune disease in
rodents. Studies using arthritic mice and rats also dem-
onstrate that inhibition of IL-21 expression correlates
with modulation of serum IL-6 levels and improvements
Figure 3 Meta-analysis of the KIAA1109-TENR-IL2-IL21 SNP, rs907715. Combined odds ratio values from WTCCC [22] and the Australasian case-
control sample sets. There was no evidence for heterogeneity between sample sets (P = 0.48).
Odds ratio
.841632 1 1.18817
Study  % Weight
 Odds ratio
 (95% CI)
 0.92 (0.84,1.00)  WTCCC  71.0
 0.97 (0.85,1.11)  Australasian  29.0
 0.93 (0.87,1.00)  Overall (95% CI)Hollis-Moffatt et al. Arthritis Research & Therapy 2010, 12:R116
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Table 3: Association analysis of the KIAA1109-TENR-IL2-IL21 SNPs rs17388568 and rs907715 with RA in three European 
Caucasian case-control sample sets
Genotype, no. (frequency)1,2 Minor allele, no. 
(frequency)
OR [95% CI] P
Sample Set 1/1 1/24 2/2
rs17388568
WTCCC [22]
Case 938 (0.505) 773 (0.416) 145 (0.078) 1,063 (0.286) 1.14 (1.04 to 1.25) 0.005
Control 1,610 (0.549) 1,119 (0.381) 204 (0.070) 1,527 (0.260)
Barton [12]
Case 2,057 (0.528) 1,530 (0.393) 308 (0.079) 2,146 (0.275) 0.97 (0.91 to 1.05) 0.47
Control 1,797 (0.516) 1,415 (0.406) 271 (0.077) 1,957 (0.281)
Australasian
Case 453 (0.543) 305 (0.366) 76 (0.091) 457 (0.274) 1.03 (0.90 to 1.19) 0.654
Control 584 (0.584) 461 (0.415) 67 (0.060) 595 (0.268)
rs907715
WTCCC [22]
Case 835 (0.450) 822 (0.443) 199 (0.107) 1,220 (0.329) 0.92 (0.84 to 1.00) 0.055
Control 1,251 (0.427) 1,324 (0.451) 358 (0.122) 2,040 (0.349)
Australasian
Case 365 (0.438) 374 (0.449) 94 (0.113) 562 (0.337) 0.98 (0.86 to 1.12) 0.687
Control 468 (0.421) 524 (0.471) 120 (0.108) 764 (0.344)
(1) There was one significant departure from Hardy-Weinberg equilibrium, P = 0.02 in Australasian cases
(2) Genotype data were imputed in the WTCCC sample set for rs907715, and directly genotyped in all others
Table 4: Logistic regression analyses of the rs6822844 genotype frequencies in Australasian RA patients according to sub-
phenotype
rs6822844
GG GT TT P
Gender
Male 181 (0.69) 72 (0.28) 9 (0.03) 0.997
Female 352 (0.69) 139 (0.27) 17 (0.03)
Rheumatoid factor
Yes 419 (0.70) 155 (0.26) 22 (0.04) 0.834
No 95 (0.70) 38 (0.28) 3 (0.02)
anti-CCP
Yes 232 (0.70) 87 (0.26) 12 (0.04) 0.511
No 103 (0.66) 50 (0.32) 4 (0.03)
SE status
0 133 (0.69) 45 (0.28) 5 (0.03) 0.974
1 or 2 456 (0.70) 168 (0.26) 25 (0.04)
Anti-CCP, anti-cyclic citrullinated peptide antibodies; NA, not available; RF, rheumatoid factor antibodies; SE, shared epitope statusHollis-Moffatt et al. Arthritis Research & Therapy 2010, 12:R116
http://arthritis-research.com/content/12/3/R116
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in disease severity [36]. However, it remains to be deter-
mined whether inhibition of IL-21 in humans with RA
will have a similar beneficial effect given the significant
differences between Th17 cell biology in mice and men.
Given the importance of Th17 cells in autoimmunity
[37], the differential genetic effects observed in various
autoimmune phenotypes mediated by the IL23R  and
KIAA1109-TENR-IL2-IL21 regions, evidence for genetic
interaction between the KIAA1109-TENR-IL2-IL21
region and IL23R (in ulcerative colitis at least) [38], there
are reasonable grounds for considering the hypothesis
that genetic control of the Th1/Th17 axis is centered on
cytokines (and their receptors) important in Th17 biol-
ogy. It is important to note that not all RA patients have
evidence of IL-17A within synovial tissue [39] and the
role of IL-17A appears to be as an amplifier of inflamma-
tion rather than an absolute requirement for inflamma-
tion in RA. One possible explanation is genetic variation
in the KIAA1109-TENR-IL2-IL21  locus that results in
non-functional IL-21 and hence lack of IL-17A or vice
versa. Regulation of this axis may be an important factor
in determining the risk to particular autoimmune pheno-
types, which may have implications for selection of tar-
geted biological therapies within an individual. What will
be important in understanding molecular control of auto-
immunity will be association studies in large sample sets
from different autoimmune phenotypes that comprehen-
sively capture common variation in the IL23R  and
KIAA1109-TENR-IL2-IL21  loci, fine-mapping of the
genetic effects and analysis of interaction between the
disease-associated variants, both within and between
loci.
Conclusions
Genotyping of an Australasian RA case-control sample
set, and meta-analysis with published and publicly-avail-
able data confirm at a genome-wide level of significance
the rs6822844 SNP within the KIAA1109-TENR-IL2-IL21
locus to be a risk factor in RA (P = 2.1 × 10-8; OR = 0.86).
There was no evidence for an independent effect on RA
mediated by other variants within the KIAA1109-TENR-
IL2-IL21 locus, as is seen in type 1diabetes.
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